| 56602-6 |
11-Deoxycorticosterone^1st specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56602-6 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC sp1 p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 21-Hydroxyprogesterone; Acute specimen; After; CHEMISTRY.CHALLENGE TESTING; DOC; First; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Pre immunization; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp1; sp1 p chal; Spec; SR |
2.73 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56603-4 |
11-Deoxycorticosterone^2nd specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56603-4 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC sp2 p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 21-Hydroxyprogesterone; After; CHEMISTRY.CHALLENGE TESTING; Convalescent; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Post immunization; PST; QNT; Quan; Quant; Quantitative; Random; Second; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp2; sp2 p chal; Spec; SR |
2.73 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56604-2 |
11-Deoxycorticosterone^3rd specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56604-2 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC sp3 p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 21-Hydroxyprogesterone; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp3; sp3 p chal; Spec; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56605-9 |
11-Deoxycorticosterone^4th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56605-9 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC sp4 p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 21-Hydroxyprogesterone; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp4; sp4 p chal; Spec; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56606-7 |
11-Deoxycorticosterone^pre XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --pre XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56606-7 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC pre chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 21-Hydroxyprogesterone; Before; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre chal; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.32 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56608-3 |
11-Deoxycorticosterone^15M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56608-3 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC 15M p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 15M p chal; 21-Hydroxyprogesterone; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56609-1 |
11-Deoxycorticosterone^20M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56609-1 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC 20M p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 20M p chal; 21-Hydroxyprogesterone; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 5661-4 |
Gold |
MRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Gold [Mass/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/24 H |
|
|
|
|
|
|
DRUG/TOX |
|
5661-4 |
|
|
|
|
Both |
|
|
|
0 |
Gold 24h Ur-mRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; AU; DRUG/TOXICOLOGY; Drugs; Mass rate; mRate; QNT; Quan; Quant; Quantitative; UA; UR; Urn |
2.42 |
1 |
|
|
|
|
|
|
|
mg/(24.h) |
|
|
|
0 |
| 56610-9 |
11-Deoxycorticosterone^40M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56610-9 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC 40M p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 21-Hydroxyprogesterone; 40M p chal; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56611-7 |
11-Deoxycorticosterone^1.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56611-7 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC 1.5h p chal SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 11DOC; 11-DOC; 21-Hydroxyprogesterone; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56612-5 |
11-Deoxycorticosterone^2H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56612-5 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC 2h p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 120 min; 120 minutes; 120min; 2 hours; 21-Hydroxyprogesterone; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56613-3 |
11-Deoxycorticosterone^2.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56613-3 |
|
|
|
|
Observation |
|
|
|
0 |
11DOC 2.5h p chal SerPl-mCnc |
|
|
|
N |
|
11DOC; 11-DOC; 2.5h p chal; 21-Hydroxyprogesterone; After; CHEMISTRY.CHALLENGE TESTING; DOC; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56614-1 |
17-Hydroxyprogesterone^10M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56614-1 |
|
|
|
|
Observation |
|
|
|
0 |
17OHP 10M p chal SerPl-mCnc |
|
|
|
N |
|
10M p chal; 17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Genetics; Heredity; Heritable; Hydroxyproges; Hydroxyprogstron; Inherited; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56615-8 |
17-Hydroxyprogesterone^20M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56615-8 |
|
|
|
|
Observation |
|
|
|
0 |
17OHP 20M p chal SerPl-mCnc |
|
|
|
N |
|
17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; 20M p chal; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Genetics; Heredity; Heritable; Hydroxyproges; Hydroxyprogstron; Inherited; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56616-6 |
17-Hydroxyprogesterone^1.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56616-6 |
|
|
|
|
Observation |
|
|
|
0 |
17OHP 1.5h p chal SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Genetics; Heredity; Heritable; Hydroxyproges; Hydroxyprogstron; Inherited; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56617-4 |
17-Hydroxyprogesterone^2H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56617-4 |
|
|
|
|
Observation |
|
|
|
0 |
17OHP 2h p chal SerPl-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Genetics; Heredity; Heritable; Hydroxyproges; Hydroxyprogstron; Inherited; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56618-2 |
Insulin-like growth factor-I^10M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
CHAL |
|
56618-2 |
|
|
|
|
Observation |
|
|
|
0 |
IGF-I 10M p chal SerPl-mCnc |
|
|
|
N |
|
10M p chal; After; CHEMISTRY.CHALLENGE TESTING; Fac; Fact; Factor 1; FI; HUM; Humulin; IGF; IGF1; IGF-1; IGF-I; IH7; Insul; Lente; Level; Mass concentration; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatomedin C; SR; Ultralente |
2.34 |
2.29 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 56619-0 |
Insulin-like growth factor-I^20M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
CHAL |
|
56619-0 |
|
|
|
|
Observation |
|
|
|
0 |
IGF-I 20M p chal SerPl-mCnc |
|
|
|
N |
|
20M p chal; After; CHEMISTRY.CHALLENGE TESTING; Fac; Fact; Factor 1; FI; HUM; Humulin; IGF; IGF1; IGF-1; IGF-I; IH7; Insul; Lente; Level; Mass concentration; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatomedin C; SR; Ultralente |
2.34 |
2.29 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 5662-2 |
Heavy metals |
PrThr |
Urine |
Pt |
Ord |
Reinsch |
|
ACTIVE |
Heavy metals [Presence] in Urine by Reinsch |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
5662-2 |
|
Reinsch |
|
|
Both |
|
|
|
0 |
Heavy Metals Ur Ql Reinsch |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Heavy met; Metal; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 56620-8 |
Elastase Ab |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Elastase Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
56620-8 |
|
IA |
|
|
Both |
|
|
|
0 |
Elastase Ab Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; EIA; ELA; ELFA; ELISA; Enzyme immunoassay; IAA; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; SUDS |
2.69 |
2.29 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 56621-6 |
Coxsackievirus A9 Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A9 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
56621-6 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A9 IgG Titr CSF IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Cerebral spinal fluid; Cerebrospinal Fl; Coxsackie; Coxsackie virus; CV; CV A9; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.29 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 56622-4 |
Echovirus Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Echovirus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
56622-4 |
|
IF |
|
|
Both |
|
|
|
0 |
ECV IgG Titr CSF IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); Echo; Echo virus; ECV; EV; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.29 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 56623-2 |
Echovirus Ab.IgM |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Echovirus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
56623-2 |
|
IF |
|
|
Both |
|
|
|
0 |
ECV IgM Titr CSF IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); Echo; Echo virus; ECV; EV; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.29 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 56624-0 |
Fructose |
SCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Fructose [Moles/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
56624-0 |
|
|
|
|
Both |
|
|
|
0 |
Fructose Ser-sCnc |
|
|
|
N |
|
Chemistry; Level; Levulose; Point in time; QNT; Quan; Quant; Quantitative; Random; Revulose; Serum; SR; Substance concentration |
2.42 |
2.29 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 56625-7 |
Methylene chloride |
SCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Methylene chloride [Moles/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
56625-7 |
|
|
|
|
Both |
|
|
|
0 |
DCM Bld-sCnc |
|
|
|
N |
|
Addiction; Blood; Cl; Cl-; DCM; Dichloromethane; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Substance concentration; WB; Whole blood |
2.42 |
2.29 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
